Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 5/5 criteria met. Data as of 28/10/2026.
- ✅ Price trend passed
- ✅ Growth passed
- ✅ Debt passed
- ✅ P/E passed
- ✅ Correction passed
Price trend
Overall trend (8 years): the price has been multiplied by at least 1.5.
Price change 2018 → 2019: 18.83%
Price change 2019 → 2020: 2.69%
Price change 2020 → 2021: 82.24%
Price change 2021 → 2022: -22.12%
Price change 2022 → 2023: -14.56%
Price change 2023 → 2024: 8.04%
Price change 2024 → 2025: 26.89%
Price change 2025 → 2026: -13.22%
Price change 2026 (year to date): -11.52%
Financial growth
Revenue CAGR (8 years): 5.98%
Earnings CAGR (8 years): 4.88%
Growth status: positive trend (>1%/yr) in revenue and earnings.
Debt
Debt-to-equity ratio: 0.22
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 15.20
P/E < 25.0 (maximum threshold).
Correction (6 months)
Current correction: 16.02% from the high over 6 months.
Correction between 10.0% and 20.0% (target range).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="AUB.PA" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Aubay S.A. | 15.0 | 0.22 | +9.0 % | 🔒 |
| Worldline S.A. | – | 0.96 | +10.3 % | – |
| Quadient S.A. | – | 0.99 | +0.8 % | – |
| Lectra S.A. | 17.7 | 0.32 | +6.8 % | – |
| Neurones S.A. | 16.1 | 0.09 | +8.9 % | ★ 4/5 |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|